Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, broaden investor appeal, and align trading conditions with the interests of shareholders. Following the split, shares will trade on the NYSE American under the current ticker 'CLDI' but with a new CUSIP number, 320703 408.

The reverse stock split will convert every 12 pre-split shares into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level. This adjustment will proportionally affect outstanding options, warrants, and equity plan shares, though it will not alter the par value or the number of authorized shares. The decision underscores Calidi Biotherapeutics' commitment to strengthening its market position and enhancing shareholder value as it continues to develop its targeted genetic medicine delivery platforms.

For further details on the announcement, visit https://ibn.fm/qFW3H.